


Biomatter
Also known as Biomatter Designs
Founded by researchers who met at Vilnius University's Institute of Biotechnology; designs enzymes for a customer's target reaction with generative and physics-based models, tests each design in the lab before it ships, and sells them as custom programmes to drugmakers, reagent suppliers and food, agriculture and industrial biotech companies.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-11-12Series ARound
$18M
For: a 2,000 m² design-and-testing facility in Vilnius opening in 2027, a larger commercial team and US presence, and continued work on the computational platform and its enzyme dataset
Wet labCommercial roll-outData generation
The company's release of 12 November calls the round oversubscribed and quotes Harry Briggs of Astanor and Oliver Schoppe of UVC Partners; it was distributed on Business Wire, as TNW's report of the same day says. No valuation was disclosed.
Lead · Astanor
Existing investor · UVC Partners
Existing investor · InventureExisting investor · MetaplanetOn the deal: Harry Briggs (Partner; spoke for the lead in the announcement, Astanor); Oliver Schoppe (Partner; spoke for the firm in the announcement, UVC Partners)
- 2024-08-05SeedRound
€6.5M≈ $7.13M
For: expand the platform's capabilities and design de novo enzymes
Models and platform
The company's release calls the round jointly led and names existing investors Practica Capital and Metaplanet as taking part, with angels and industry specialists not named.
Co-lead · Inventure
Co-lead · UVC PartnersExisting investor · Practica CapitalExisting investor · Metaplanet
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.